pharmacokinetics of antidepressants - inhn:...
TRANSCRIPT
![Page 1: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/1.jpg)
Pharmacokinetics of
AntidepressantsJose de Leon, MD
(11-01-15)
![Page 2: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/2.jpg)
Learning ObjectivesAfter completing this presentation, the participant should
be able to:
1) Appreciate the relevance of absorption, renal and
hepatic impairment for some antidepressants.
3) Summarize major metabolic pathways of:
(a) tricyclic antidepressants,
(b) selective serotonin reuptake inhibitors,
(c) selective noradrenergic reuptake inhibitors, and
(d) others.
4) Be aware that antidepressants can be involved in
clinically-relevant drug-drug interactions since:
(a) some antidepressants are inhibitors, and
(b) inducers, inhibitors and pregnancy can influence
their metabolism.
![Page 3: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/3.jpg)
WarningThis is an extraordinarily long presentation:
1) You may need to read it more than once until you have
become familiar with key aspects. More importantly,
you need to practice every day and review the pharma-
cokinetics of drugs when any of your patients are
taking antidepressants in the context of polypharmacy.
3) The most important concept to remember is that some
antidepressants are clinically significant inhibitors of
the metabolism of some other drugs. See the “Do Not
Forget” Section. See important facts in red.
4) The section on CYP genotyping is very complex if
you are not familiar with these concepts. If you want
to understand it better, please review the lecture titled,
“Pharmacogenetic Testing in Psychiatry”.
![Page 4: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/4.jpg)
Abbreviations■ ADR: adverse drug reaction■ AED: antiepileptic drug■ C: concentration■ C/D ratio: concentration-to-dose ratio■ CYP: cytochrome P450■ CYP2C: CYP2C8, CYP2C9 & CYP2C19 ■ D: dose
■ DDI: drug-drug interaction■ GFR: glomerular filtration rate■ nor=desmethyl when describing metabolites.
norclomipramine=desmethylclomipramine■ TDM: therapeutic drug monitoring
■ UGT: uridine diphosphate glucuronosyltransferase
![Page 5: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/5.jpg)
Abbreviations of Included Antidepressants
This presentation focuses on:■ TCAs: tricyclic antidepressants
Only 5 TCAs are described. ■ SNRIs: serotonin-norepinephrine
inhibitors ■ SSRIs: selective serotonin reuptake
inhibitors■ The rest are included in “Others.”
![Page 6: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/6.jpg)
Antidepressants That Are Not Included
■ MAOIs: monoamine oxidase inhibitors
■ nefazadone
![Page 7: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/7.jpg)
Described Antidepressants Not Marketed in the US
■ agomelatine■ milnacipran■ reboxetine
![Page 8: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/8.jpg)
Signs Used for Dosing and to Correct for DDIs
■ Arrows:
□ ↑: increase D.
□ ↓: decrease D.
■ Correction factor; use this number to multiply by
the average daily D to correct for DDIs.
Inducers > 1 (e.g., x 2 D, multiply D by 2)
Inhibitors < 1 (e.g., 0.5 D, multiply D by 0.5)
■ Potent AED inducers are:
□ carbamazepine
□ phenytoin
□ phenobarbital
![Page 9: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/9.jpg)
Examples of a Correction Factor
■ The risperidone correction factor for
□ carbamazepine = 2 x D
□ paroxetine = 0.5 x D
■ If you use 4 mg/day of risperidone in a typical
patient,
□ In a carbamazepine patient, you should use
8 mg/day risperidone (2 x 4 mg/day = 8 mg/day).
□ In a paroxetine patient, you should use
2 mg/day risperidone (0.5 x 4 mg/day = 2
mg/day).
![Page 10: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/10.jpg)
Lecture Content0. CYP Terminology
1. Absorption
2. Renal Elimination
3. Metabolism
4. Hepatic Impairment
5. Pregnancy 6. Do Not Forget
![Page 11: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/11.jpg)
Lecture Content0. CYP Terminology
0.1. Definitions 0.2. CYP2D6 0.3. CYP2C19
1. Absorption 1.1. Absorption: Food
2. Renal Elimination2.1. No Good Reviews on Renal Elimination2.2. Chronic Kidney Disease 2.3. Recent Drugs
3. Metabolism3.1. TCAs3.2. SSRIs 3.3. SNRIs3.4. Others
4. Hepatic Impairment4.1. Severity4.2. Antidepressants
5. Pregnancy 6. Do Not Forget
6.1. Some Antidepressants are Inhibitors6.2. Other Drugs May Influence Antidepressants
![Page 12: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/12.jpg)
0. CYP Terminology
(only for the brave of
heart)
![Page 13: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/13.jpg)
0. CYP Terminology
0.1. Definitions
0.2. CYP2D6
0.3. CYP2C19
![Page 14: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/14.jpg)
0.1. CYP Definitions
![Page 15: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/15.jpg)
0.1 CYP Definitions
0.1.1. Phenotype
0.1.2. Allele *1
0.1.3. Two Alleles for a Phenotype
![Page 16: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/16.jpg)
0.1.1. Phenotype
![Page 17: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/17.jpg)
0.1.1. Phenotype
■ Everyone has two alleles which determine his/her phenotype.
■ Phenotype =
“The outward appearance of the individual.
It is the product of interactions between
genes, and between the GENOTYPE and
the environment.”http://www.ncbi.nlm.nih.gov/mesh/?term=phenotype
![Page 18: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/18.jpg)
0.1.1. Phenotype
■ Phenotype abbreviations:
□ UM: ultrarapid metabolizer (↑ activity),□ EM: extensive metabolizer
(normal activity),□ IM: intermediate metabolizer (low activity),□ PM: poor metabolizer (no activity).
![Page 19: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/19.jpg)
0.1.1. Phenotype
■ Unfortunately, this terminology is confusing.
It means different things for CYP2D6 and
CYP2C19 and different labs use it differently.
Ordering tests without understanding CYP
terminology may be wasting money.
■ CYP2D6 and CYP2C19 are polymorphic.
Polymorphisms are usually defined as those
genetic variations present in at least 1% of the
population. Absence of CYP2D6 or CYP2C19
is present in >1% of the population.
![Page 20: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/20.jpg)
0.1.2. Allele *1
![Page 21: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/21.jpg)
0.1.2. Allele *1
■ The most important concept to understand
results from CYP genotyping. If you do not
understand this, you will misinterpret any
CYP genotyping that you order.
■ Allele 1 or *1:
□ is the normal (called “wild type”) allele.
□ is not determined by the lab. A laboratory
will call an allele *1 when none of the
abnormal alleles that laboratory tests is
found. Think carefully about this before
moving to the next slide.
![Page 22: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/22.jpg)
0.1.2. Allele *1
■ Imagine two hypothetical labs:
□ One lab only tests for *2 and *3. This lab
will find many *1s.
□ One tests for *2, *3, *4, *5, *6, *7, *8 and
*9. This lab will find considerably fewer *1s.
This is a paradoxical situation: a poor lab will find
many more *1s and many more normal subjects than
a good lab. Moreover, a clinician using a poor lab
will think that many of the patients are normal
when, as matter of fact, they are not.
![Page 23: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/23.jpg)
0.1.2. Allele *1
■ This has very relevant clinical implications:
□ CYP2C19 is a very simple gene.
Most US labs doing CYP genotyping can be
trusted for CYP2C19 genotyping.
□ CYP2D6 is a very complex gene.
Most US labs doing CYP genotyping
CANNOT be trusted for some aspects of
CYP2D6 genotyping.
See the sections on practical rules for CYP2D6
and CYP2C19 genotyping for more details.
![Page 24: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/24.jpg)
0.1.3. Two Alleles for a
Phenotype
![Page 25: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/25.jpg)
0.1.3. Two Alleles for a Phenotype
■ A subject *1/*17: has an allele 1 and
an allele 17.
The order is not important. *1/*17 = *17/*1
■ Be very careful concerning the allele number:□ It reflects the order in which it was discovered.
□ It has no relationship with activity level.
● CYP2D6 *17: typical of Africans
↓ activity (or normal
for risperidone).
● CYP2C19 *17: typical of Caucasians
↑ activity (↑ expression)
![Page 26: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/26.jpg)
0.2. CYP2D6 Terminology
![Page 27: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/27.jpg)
0.2. CYP2D6 Terminology
0.2.1. CYP2D6 Phenotypes
0.2.2. CYP2D6 Alleles
0.2.3. CYP2D6 Phenotypes and Alleles
0.2.4. CYP2D6 Phenotypes and Race
0.2.5. CYP2D6 Genotyping Practical
Rules
![Page 28: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/28.jpg)
0.2.1. CYP2D6 Terminology
![Page 29: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/29.jpg)
0.2.1. CYP2D6 Terminology
Preferred by Dr. de Leon http://www.ncbi.nlm.nih.gov/pubmed/19169185
Phenotype N active copies
Ultrarapid metabolizer (UM) ≥3
Extensive metabolizer (EM) 1 to <3
Intermediate metabolizer (IM) 0 to <1
Poor metabolizer (PM) 0
Used by Some Labs
Phenotype N active copies
Ultrarapid metabolizer (UM) ≥3
Extensive metabolizer (EM) >1 to <3
Intermediate metabolizer (IM) ≤1
Poor metabolizer (PM) 0
![Page 30: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/30.jpg)
0.2.2. CYP2D6 Alleles
![Page 31: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/31.jpg)
0.2.2. The Most Important CYP2D6 Alleles
■ CYP2D6*1xn or *2xn: increased number of copies.
“x” refers to multiplication. It is usually double but can be
more. Labs do not usually distinguish doubling (most
frequent) from other forms of multiplication.
■ CYP2D6*1 (allele 1) is the normal allele.
CYP2D6*2 (allele 2) is usually considered a normal allele.
■ CYP2D6*17 (allele 17) is typical of Africans. It has low
activity for many (but not all) CYP2D6 substrates.
■ CYP2D6*10 (allele 10) is typical of East Asians. It has
very low activity for CYP2D6 substrates.
■ CYP2D6*3,*4,*5 and *6 (alleles 3, 4, 5 and 6) are the
most important null alleles with no activity.
![Page 32: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/32.jpg)
0.2.3. CYP2D6 Phenotypes
and Alleles
![Page 33: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/33.jpg)
0.2.3. CYP2D6 Phenotypes and Alleles
Alleles Phenotype
*1xn/*1 or *2xn/*1 UM
*1/*1, *1/*2 or *2/*2 EM
*1/*3, *1/*4, *1/*5 & *1/*6 EM/IM
or *2/*3, *2/*4, *2/*5 & *2/*6
*10/*10 IM (very low)
any combination *3,*4,*5 or *6: PM
*3/*3, *3/4, *3/5, *3/6, *4/*4,
*4/5, *4/6, *5/*5, *5/*6 & *6/*6
![Page 34: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/34.jpg)
0.2.4. CYP2D6 Phenotypes
and Race
![Page 35: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/35.jpg)
0.2.4. CYP2D6: Phenotype and Race
■ CYP2D6 PMs (no CYP2D6):
□ Caucasians: approximately 7%
□ Other races: 1-3 (<5%)
■ CYP2D6 IMs (with low activity):
□ East Asians: 2-3%
● *10/*10: activity of 0.05 (vs. 2 in *1/*1)
□ Africans (*17): 2-3%
● *17/*17: low CYP2D6 activity for many drugs
■ CYP2D6 UMs (≥ 3 copies of active alleles):
with 3: activity of 3.4 (vs. 2 in *1/*1) http://www.ncbi.nlm.nih.gov/pubmed/21866098
□ North Africa: 40%
□ Oceania: >20%
□ Caucasians: 1-5%
□ USA: 1-2%
![Page 36: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/36.jpg)
0.2.5. Practical Rules for
CYP2D6 Genotyping
![Page 37: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/37.jpg)
0.2.5. Practical Rules for CYP2D6 Genotyping
This reflects Dr. de Leon’s experience with US labs:
■ CYP2D6 PMs: Most labs are reliable.
■ CYP2D6 IMs: Be careful
□ Is this a subject with low activity?
□ Is this a subject with at least *1 allele and relatively
normal activity?
■ CYP2D6 EMs:
□ good labs: result is probably reliable.
□ poor labs: subject may be CYP2D6 IM or UM.
■ CYP2D6 UMs:
□ good labs: result is probably reliable.
□ poor labs: may be missing CYP2D6 UMs or
identifying as CYP2D6 UM subjects that are
not CYP2D6 UMs.
![Page 38: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/38.jpg)
0.3. CYP2C19 Terminology
![Page 39: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/39.jpg)
0.3. CYP2C19 Terminology
0.3.1. CYP2C19 Phenotypes
0.3.2. CYP2C19 Alleles
0.3.3. CYP2C19 Phenotypes and Alleles
0.3.4. CYP2C19 Phenotypes and Race
0.3.5. Practical Rules for CYP2C19
Genotyping
![Page 40: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/40.jpg)
0.3.1. CYP2C19 Phenotypes
![Page 41: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/41.jpg)
0.3.1. CYP2C19 Phenotypes
Terminology Preferred by Dr. de Leon
Phenotype N active copies
Ultrarapid metabolizer (UM) ↑ expression
Extensive metabolizer (EM) 1 or 2
Poor metabolizer (PM) 0c
Terminology Used by Some Labs
Phenotype N active copies
Ultrarapid metabolizer (UM) ↑ expression
Extensive metabolizer (EM) 2
Intermediate metabolizer (IM) 1
Poor metabolizer (PM) 0c
![Page 42: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/42.jpg)
0.3.2. CYP2C19 Alleles
![Page 43: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/43.jpg)
0.3.2. The Most Important CYP2C19 Alleles
■ CYP2C19*17 (allele 17): increased
expression. There is no agreement about
its clinical relevance.
■ CYP2C19*1 (allele 1) is the normal allele.
■ CYP2C19*2 and *3 (alleles 2 and 3) are null
alleles. Other more rare alleles are also null
alleles.
![Page 44: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/44.jpg)
0.3.3. CYP2C19 Phenotypes
and Alleles
![Page 45: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/45.jpg)
0.3.3. CYP2C19 Phenotypes and Alleles
Alleles Activity Phenotype
*17/*17 ↑ ↑ expression UM
*1/*17 ↑ expression UM some labs
*1/*1 normal EM some labs
*1/*2 or *1/*3 lower EM some labs
IM some labs
*2 /*2 or*3/*3 no PM
or *2/*2
![Page 46: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/46.jpg)
0.3.4. CYP2C19 Phenotypes
and Race
![Page 47: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/47.jpg)
0.3.4. CYP2C19: Phenotype and Race
■ CYP2C19 PMs:
□ East Asians: 25 %
□ Other races: <5%
■ CYP2C19 UMs:
*17: associated with ↑ expression
Clinical relevance not well established.
□ Frequency 1-5% *17/*17
□ Higher frequency with only one *17
![Page 48: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/48.jpg)
0.3.5. Practical Rules for
CYP2C19 Genotyping
![Page 49: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/49.jpg)
0.3.5. Practical Rules for CYP2C19 Genotyping
This reflects Dr. de Leon’s experience with US labs:
■ CYP2C19 PMs: Most labs are reliable.
■ CYP2C19 IMs: Be careful
□ Is this a subject with at least *1 allele and
relatively normal activity?
■ CYP2C19 EMs: Most labs are probably reliable.
■ CYP2C19 UMs:
□ good labs: probably reliable but the literature
does not agree on clinical relevance.
![Page 50: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/50.jpg)
Antidepressant Pharmacokinetics
1. Absorption
2. Renal Elimination
3. Metabolism
4. Hepatic Impairment
5. Pregnancy
![Page 51: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/51.jpg)
1. Antidepressant
Absorption
![Page 52: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/52.jpg)
1. Absorption
1.1. Absorption: Food
![Page 53: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/53.jpg)
1.1. Absorption: Food
■ An antidepressant that NEEDs to be administered with food:
□ vilazodone
![Page 54: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/54.jpg)
2. Antidepressants:
Renal Elimination
![Page 55: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/55.jpg)
2. Antidepressants: Renal Elimination
2.1. No Good Reviews on Renal Elimination
2.2. Chronic Kidney Disease
2.3. Recent Drugs
![Page 56: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/56.jpg)
2.1. Renal Elimination:
Antidepressant
![Page 57: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/57.jpg)
2.1. Antidepressants: Renal Elimination
■ No good comparative reviews.
■ Some antidepressants are mainlyeliminated by the kidney:□ desvenlafaxine,□ levomilnacipran, and □ milnacipran.These 3 antidepressant are not good antidepressants for patients with renal impairment.
![Page 58: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/58.jpg)
2.2. Chronic Kidney Disease
![Page 59: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/59.jpg)
2.2. Chronic Kidney Disease 2012 recommendations by European Renal Best Practice:
Based on a summary of 28 studies for 24 antidepressants:
■ ↓ dose for:
□ TCAs:
● clomipramine□ SNRIs:
● desvenlafaxine:● venlafaxine:
□ Others: ● bupropion:● milnacipran ● reboxetine ● selegiline (MAOI)● tianeptine (not marketed in the US)
http://www.ncbi.nlm.nih.gov/pubmed/22859791
![Page 60: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/60.jpg)
2.2. Chronic Kidney Disease
Bautovich et al., 2014 (comprehensive literature review):http://www.ncbi.nlm.nih.gov/pubmed/24658294
■ ↑ risk for ADRs on all antidepressants
■ Recommendations on drugs to avoid:
□ duloxetine: GFR< 30 ml/min: contraindicated
GFR> 30 ml/min: start a low D
↑ D slowly
■ Recommendations on drugs to use (next slide)
![Page 61: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/61.jpg)
2.2. Chronic Kidney Disease ■ Recommended antidepressants: http://www.ncbi.nlm.nih.gov/pubmed/24658294
□ Evidence available suggests they are usually safe but may
require additional monitoring and dose ↓:
● citalopram: use with caution when GFR < 10ml/min ● fluoxetine: GFR < 20ml/min: ↓ dose or alternate days
□ Evidence available can be used but greater caution is needed):● amitriptyline: start low and increase slowly
TDM may be useful● mirtazapine: GFR = 10-50 ml/min: dose as usual
GFR < 10 ml/min: start low dose and increase slowly
● paroxetine: GFR < 30 ml/min: start 10-20 mg/dayand increase slowly
● sertraline: no dose adjustment required
● venlafaxine: GFR < 30 ml/min: avoid slow-release
formulation
![Page 62: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/62.jpg)
2.3. Renal Impairment:
Recent Drugs
![Page 63: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/63.jpg)
2.3. Renal Impairment: Recent Drugs
■ Vilazadone: no need for D correction
even in end-stage renal disease
http://www.ncbi.nlm.nih.gov/pubmed/25474324
■ Vortioxetine: no need for D correction
in mild-to-moderate renal impairment
http://www.ncbi.nlm.nih.gov/pubmed/25650679
![Page 64: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/64.jpg)
3. Antidepressant
Metabolism
![Page 65: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/65.jpg)
3. Metabolism
3.1. TCAs
3.2. SSRIs
3.3. SNRIs
3.4. Others
![Page 66: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/66.jpg)
3.1. TCAs
![Page 67: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/67.jpg)
3.1. TCAs
3.1.1. Metabolic Enzymes
3.1.2. CYP Genotyping
3.1.3. TDM
3.1.4. DDIs
![Page 68: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/68.jpg)
3.1.1. TCAs:
Metabolic Enzymes
![Page 69: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/69.jpg)
3.1.1. TCAs: Metabolic Enzymes
■ Chemical classification:
□ Tertiary amines:
Compounds (and active metabolite):
● amitriptyline (nortriptyline)
● clomipramine (nordesmethylclomipramine)
● imipramine (desipramine)
□ Secondary amines:
Compounds:
● nortriptyline
● desipramine
Less ADRs than tertiary amines
![Page 70: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/70.jpg)
3.1.1. TCAs: Metabolic Enzymes
■ Tertiary amines:
□ Desmethylation: CYP2C19 (CYP1A2,
CYP2C9 and CYP3A4)
□ Hydroxylation of active metabolite:
CYP2D6
■ Secondary amines: Hydroxylation: CYP2D6
![Page 71: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/71.jpg)
3.1.1. TCAs: Metabolic Enzymes■ Dr. de Leon’s reminder: this is in normal circumstances:
□ Tertiary amines: CYP2C19 and CYP2D6
□ Secondary amines: CYP2D6
■ Not well-studied under induction:
□ It is possible that CYP3A4 may become more important
■ Not well-studied under inhibition:
□ If you inhibit CYP2C19 and/or CYP2D6, other CYPs
may become more important
![Page 72: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/72.jpg)
3.1.2. TCAs:
CYP Genotyping
![Page 73: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/73.jpg)
3.1.2. TCAs: CYP Genotyping
■ Hicks et al., 2014 : http://www.ncbi.nlm.nih.gov/pubmed/23486447
□ CYP2D6 PMs: avoid TCAs or
↓ dose by 50% and use TDM for dosing
□ CYP2D6 UMs: avoid TCAs
□ CYP2C19 PMs: amitriptyline: ↓ dose by 50% and
use TDM for dosing
□ CYP2C19 UMs: amitriptyline: select another
antidepressant not metabolized by CYP2C19
□ CYP2C19 PM/UMs: recommendations for amitriptyline
probably apply to clomipramine and imipramine
![Page 74: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/74.jpg)
3.1.3. TCAs:
TDM
![Page 75: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/75.jpg)
3.1.3. TCAs: TDM■ Preskorn: http://www.ncbi.nlm.nih.gov/pubmed/8407856
He uses the concentration/dose (C/D) ratio.
C: ng/ml. D: mg/day.
After getting steady-state trough TDM,
the C/D ratio indicates CYP2D6 activity:
□ <0.5: Patient is: ● CYP2D6 UM, or
● non-compliant
□ 0.5-1.5: Patient is CYP2D6 EM
□ >1.5: Patient is: ● CYP2D6 PM, or
● taking a potent CYP2D6 inhibitor.
■ Additional reminders by Dr. de Leon:
□ Inducers may provide low C/D ratios.
□ CYP2C19 PMs may provide high C/D ratios
in tertiary amines.
![Page 76: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/76.jpg)
3.1.3. TCAs: TDM
■ Therapeutic ranges: http://www.ncbi.nlm.nih.gov/pubmed/22053351
□ amitriptyline + nortriptyline: 80-200 ng/mL
□ clomipramine + norclomipramine: 230-450 ng/mL
clomipramine: close to an SSRI
norclomipramine: close to a selective norepinephrine
reuptake inhibitor
□ desipramine: 100-300 ng/mL
□ imipramine + desipramine: 175-300 ng/mL
□ nortriptyline: 70-170 ng/mL
![Page 77: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/77.jpg)
3.1.4. TCA DDIs
![Page 78: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/78.jpg)
3.1.4. TCA DDIs
3.1.4.1. Effects of Other Drugs on TCAs
3.1.4.2. Effects of TCAs on Other Drugs
![Page 79: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/79.jpg)
3.1.4.1. Effects of Other Drugs
on TCAs
![Page 80: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/80.jpg)
3.1.4.1. DDIs: Effects of Other Drugs on TCAs
■ Inhibitors on TCAs: use TDM
□ Potent CYP2D6 inhibitors: ● fluoxetine
● paroxetine
□ Moderate CYP2D6 inhibitors: ● bupropion
● duloxetine
□ Mild CYP2D6 inhibitors:● fluvoxamine
● sertraline (dose-related)
□ CYP2C19 inhibitors: ● fluvoxamine: potent
● fluoxetine: weak to moderate
■ AED inducers on TCAs: correction factor: x 2 (1.4-2.5) D.
Use TDM
![Page 81: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/81.jpg)
3.1.4.2. Effects of TCAs
on Other Drugs
![Page 82: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/82.jpg)
3.1.4.2. DDIs: Effects of TCAs on Other Drugs
■ TCAs are CYP inhibitors:
□ Tertiary amines: moderate CYP2C19 inhibitors
□ Tertiary and secondary amines: weak CYP2D6 inhibitors
![Page 83: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/83.jpg)
3.2. SSRIs
![Page 84: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/84.jpg)
3.2. SSRIs
3.2.1. Citalopram
3.2.2. Escitalopram
3.2.3. Fluoxetine
3.2.3. Fluvoxamine
3.2.4. Paroxetine
3.2.5. Sertraline
![Page 85: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/85.jpg)
3.2.1. Citalopram
![Page 86: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/86.jpg)
3.2.1. Citalopram■ The most important metabolic enzyme: CYP2C19
□ Others: CYP3A4 and CYP2D6
■ CYP2C19 genotyping
http://www.ncbi.nlm.nih.gov/pubmed/25974703
□ PMs: ● select an agent not dependent on CYP2C19, or
● correct by 0.50 x initial D and
titrate accordingly
□ UMs: select an agent not dependent on CYP2C19
■ DDI with inhibitors: be careful
□ CYP2C19 inhibitors: ● fluvoxamine
● omeprazole
■ DDI with inducers: not relevant?
(correction factor 1.3 x D)
■ Effect of citalopram on other drugs: weak CYP2D6 inhibitor
In most circumstances it is not clinically relevant
![Page 87: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/87.jpg)
3.2.2. Escitalopram
![Page 88: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/88.jpg)
3.2.2. Escitalopram■ The most important metabolic enzyme: CYP2C19
□ Others: CYP3A4 and CYP2D6
■ CYP2C19 genotyping http://www.ncbi.nlm.nih.gov/pubmed/25974703
□ PMs: ● select an agent not dependent on CYP2C19, or
● correct by 0.50 x initial D and
titrate accordingly
□ UMs: select an agent not dependent on CYP2C19
■ DDI with inhibitors: probably not relevant
□ CYP2C19 inhibitors: ● fluvoxamine
● omeprazole
■ DDI with inducers: not studied
■ Effect of escitalopram on other drugs: weak CYP2D6 inhibitor
In most circumstances this is not clinically relevant
![Page 89: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/89.jpg)
3.2.3. Fluoxetine
![Page 90: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/90.jpg)
3.2.3. Fluoxetine■ The most important metabolic enzyme: CYP2D6
□ Others: CYP2C9, CYP2C19 and CYP3A4
■ Active metabolite: norfluoxetine (steady state: ● usually 2-3 months
. ● up to 6 months)
■ Non-linear kinetics: inhibits its own metabolism
■ CYP2D6 genotyping http://www.ncbi.nlm.nih.gov/pubmed/25974703
□ PMs: ● select an agent not dependent on CYP2D6, or
● correct by 0.50 x initial D and titrate accordingly
□ UMs: select another agent not dependent on CYP2D6
■ DDI with inhibitors: probably not relevant
■ DDI with inducers: probably not relevant
■ Effect of fluoxetine on other drugs:
□ potent inhibitor: CYP2D6
□ moderate inhibitor: CYP2C9
□ weak to moderate inhibitor: CYP2C19 and CYP3A4
□ weak: CYP1A2
Norfluoxetine remains for months and is more important for inhibition
![Page 91: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/91.jpg)
3.2.4. Fluvoxamine
![Page 92: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/92.jpg)
3.2.4. Fluvoxamine
■ The most important metabolic enzymes: CYP1A2 and
CYP2D6
■ CYP2D6 genotyping http://www.ncbi.nlm.nih.gov/pubmed/25974703
□ PMs: ● select an agent not dependent on CYP2D6, or
● correct by 0.50 x initial D and
titrate accordingly
□ UMs: no data
■ DDI with inhibitors: probably not relevant
■ DDI with inducers: probably not relevant
■ Effects of fluvoxamine on other drugs:
□ potent inhibitor: CYP1A2 and CYP2C19
□ moderate inhibitor: CYP2C9 and CYP3A4
□ weak inhibitor: CYP2D6
![Page 93: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/93.jpg)
3.2.5. Paroxetine
![Page 94: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/94.jpg)
3.2.4. Paroxetine■ The most important metabolic enzyme: CYP2D6
□ Other: CYP3A4
■ Non-linear kinetics: inhibits its own metabolism
■ CYP2D6 genotyping http://www.ncbi.nlm.nih.gov/pubmed/25974703
□ PMs: ● select an agent not dependent on CYP2D6, or
● correct by 0.50 x initial D and
titrate accordingly
□ UMs: select another agent not dependent on CYP2D6.
■ DDI with inhibitors: probably not relevant
■ DDI with inducers: not relevant?
(correction factor 1.3 x D)
■ Effects of paroxetine on other drugs:
□ potent inhibitor: CYP2D6
□ weak inhibitor: CYP1A2, CYP2C9, CYP2C19 and CYP3A4
![Page 95: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/95.jpg)
3.2.6. Sertraline
![Page 96: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/96.jpg)
3.2.5. Sertraline■ The most important metabolic enzyme: CYP2B6 or CYP2C19
□ Others: CYP2C9, CYP2D6, CYP3A4
■ CYP2C19 genotyping http://www.ncbi.nlm.nih.gov/pubmed/25974703
□ PMs: ● select an agent not dependent on CYP2C19, or
● correct by 0.50 x initial D and
titrate accordingly
□ UMs: start with recommended D, but if patient does not respond
consider an agent not dependent on CYP2C19
■ DDI with inhibitors: probably not relevant
■ DDI with inducers: correction factor 5 x D
■ Sertraline on other drugs:
□ weak to moderate inhibitor (dose-related): CYP2D6
□ weak inhibitor: CYP1A2, CYP2C9, CYP2C19 and CYP3A4
![Page 97: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/97.jpg)
3.3. SNRIs
![Page 98: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/98.jpg)
3.3. SNRIs
3.3.1. Desvenlafaxine
3.3.2. Duloxetine
3.3.3. Levomilnacipran
3.3.3. Milnacipran
3.3.4. Venlafaxine
![Page 99: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/99.jpg)
3.3.1. Desvenlafaxine
![Page 100: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/100.jpg)
3.3.1. Desvenlafaxine
■ Elimination:
□ Most important: renal
□ Other: UGTs and CYP3A4
■ DDI with inhibitors: probably not important
■ DDI with inducers: not studied
■ Effect of desvenlafaxine on other drugs:
rarely relevant
![Page 101: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/101.jpg)
3.3.2. Duloxetine
![Page 102: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/102.jpg)
3.3.2. Duloxetine
■ The most important metabolic enzyme: CYP1A2
□ Other: CYP2D6
■ DDI with inhibitors:
□ CYP1A2 inhibitors: consider↓ D
● fluvoxamine
● ciprofloxacin
■ DDI with inducers:
□ AED potent inducers: not studied
□ smoking: not studied
■ Effect of duloxetine on other drugs:
□ moderate CYP2D6 inhibitor
![Page 103: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/103.jpg)
3.3.3. Levomilnacipran
![Page 104: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/104.jpg)
3.3.3. Levomilnacipran
■ Elimination:
□ Most important: renal
□ Others: UGTs and CYP3A4
■ DDI with inhibitors: probably not important
■ DDI with inducers: not studied
■ Effect of levomilnacipran on other drugs:
rarely relevant
![Page 105: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/105.jpg)
3.3.4. Milnacipran
![Page 106: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/106.jpg)
3.3.4. Milnacipran ■ Elimination:
□ Most important: renal (50%)
□ Others: CYP3A4 (20%) and UGTs (30%)
■ Metabolites:
□ most metabolites are inactive
□ hydroxylated metabolite (F2782): active
but unlikely to be relevant (accounts <1% dose)
http://www.ncbi.nlm.nih.gov/pubmed/16122284
■ DDI with inhibitors: probably not important
■ DDI with inducers: not relevant?
(correction factor 1.3 x D)
■ Effect of milnacipran on other drugs:
□ mild CYP3A4 inhibitor
![Page 107: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/107.jpg)
3.3.5. Venlafaxine
![Page 108: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/108.jpg)
3.3.4. Venlafaxine■ Most important metabolic enzyme: CYP2D6
□ Other: CYP3A4
■ Active metabolite: desvenlafaxine
■ TDM: http://www.ncbi.nlm.nih.gov/pubmed/23541126
O-desmethylvenlafaxine/venlafaxine C ratio
< 1 indicates a CYP2D6 PM who may respond more poorly.
■ CYP2D6 genotyping: http://www.ncbi.nlm.nih.gov/pubmed/21412232
□ PMs : select another antidepressant or use TDM
□ UMs : correction factor x 1.5 D
■ DDI with inhibitors: not well studied: consider TDM or ↓ D
□ Potent CYP2D6 inhibitors: fluoxetine and paroxetine
□ Moderate CYP2D6 inhibitors: bupropion and duloxetine
□ Weak CYP2D6 inhibitors: fluvoxamine and sertraline
■ DDI with inducers: not studied
■ Effect of venlafaxine on other drugs: in most circumstances is not
clinically relevant, but, venlafaxine can inhibit its own metabolism
(CYP2D6 competitive inhibition).
![Page 109: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/109.jpg)
3.4. Other Antidepressants
![Page 110: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/110.jpg)
3.4. Other Antidepressants
3.4.1. Agomelatine
3.4.2. Bupropion
3.4.3. Mirtazapine
3.4.4. Reboxetine
3.4.5. Trazadone
3.4.6. Vilazadone
3.4.7. Vortioxetine
![Page 111: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/111.jpg)
3.4.1. Agomelatine
![Page 112: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/112.jpg)
3.4.1. Agomelatine■ Most important metabolic enzyme: CYP1A2
□ Other: CYP2C9
■ DDI with inhibitors: be very careful
□ Potent CYP1A2 inhibitors: ● fluvoxamine
● ciprofloxacin
□ Other CYP1A2 inhibitors: ● estrogens
● infections
■ DDI with inducers: ● AED potent inducers
● smoking
● omeprazole
■ Effect of agomelatine on other drugs: rarely relevant
![Page 113: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/113.jpg)
3.4.2. Bupropion
![Page 114: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/114.jpg)
3.4.2. Bupropion
■ Most important metabolic enzyme: CYP2B6
■ Active metabolites: □ hydroxybupropion
□ threohydrobupropion
□ erythrohydrobupropion
■ DDI with inhibitors:
□ CYP2B6 inhibitors: ● clopidogrel
● ticlopidine
■ DDI with inducers: AED potent inducers
do not co-prescribe
correction factor: x 10 D
■ Effects of bupropion: moderate CYP2D6 inhibitor
![Page 115: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/115.jpg)
3.4.3. Mirtazapine
![Page 116: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/116.jpg)
3.4.3. Mirtazapine
■ Metabolic enzymes:
□ Most important: CYP2D6 and CYP3A4
□ Others: CYP1A2 and UGTs
■ DDI with inhibitors: probably not important
■ DDI with inducers: AED potent inducers
correction factor: x 2-3 D
■ Effect of mirtazapine on other drugs: rarely
relevant
![Page 117: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/117.jpg)
3.4.4. Reboxetine
![Page 118: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/118.jpg)
3.4.4. Reboxetine
■ Metabolic enzyme: CYP3A4
■ DDI with inhibitors:
□ ketoconazole and erythromycin
□ grapefruit juice
■ DDI with inducers:
□ St John’s wort
□ AED potent inducers: not studied
Quetiapine is metabolized by CYP3A4
and has a correction factor: >5 x D.
■ Effect of reboxetine on other drugs:
rarely relevant
![Page 119: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/119.jpg)
3.4.5. Trazadone
![Page 120: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/120.jpg)
3.4.5. Trazadone
■ Metabolic enzyme: CYP3A4
■ Active metabolite metabolized by CYP2D6:
m-CPP (M-chlorophenylpiperazine):
■ DDI with inhibitors:
□ ketoconazole and erythromycin
□ grapefruit juice
■ DDI with inducers:
□ St John’s wort
□ AED potent inducers: not studied
■ Effect of trazadone on other drugs: rarely relevant
![Page 121: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/121.jpg)
3.4.6. Vilazodone
![Page 122: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/122.jpg)
3.4.6. Vilazodone■ The most important enzyme: CYP3A4
□ Others: CY2PC9, CYP2D6 and carboxylesterase
■ DDI with inhibitors: http://www.ncbi.nlm.nih.gov/pubmed/25236915
□ ketoconazole: not more than 20 mg/day
□ erythromycin and grapefruit juice
■ DDI with inducers: AED potent inducers:
□ Poor study (carbamazepine 400 mg/day for 19 days)
They recommend maximum Ds up to 80 mg/day.
Correction factor: 2 x D
□ Dr. de Leon’s opinion: higher Ds may be needed:
Quetiapine is metabolized by CYP3A4
and has a correction factor: > 5 x D.
■ Effects of vilazodone: CYP2C8 inhibitor (unclear clinical relevance)
(in vitro: moderate inhibitor of CYP2D6 and CYP2C19)
![Page 123: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/123.jpg)
3.4.7. Vortioxetine
![Page 124: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/124.jpg)
3.4.7. Vortioxetine■ The most important enzyme: CYP2D6
□ Others: CYP2A6, CYP2B6, CYP2C, CYP2D6
■ CYP2D6 PM: correction factor x 0.5 D
■ DDI with inhibitors:
□ Potent CYP2D6 inhibitors: x 0.5 D
● fluoxetine and paroxetine
□ Moderate CYP2D6 inhibitors: ● bupropion
● duloxetine
□ Mild CYP2D6 inhibitors: ● fluvoxamine
● sertraline(dose-related)
■ DDI with AED inducers: x 3 D http://www.ncbi.nlm.nih.gov/pubmed/24165478
■ Effect of vortioxetine on other drugs: rarely relevant
![Page 125: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/125.jpg)
4. Hepatic Impairment
![Page 126: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/126.jpg)
4. Hepatic Impairment
4.1. Severity
4.2. Antidepressants
![Page 127: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/127.jpg)
4.1. Hepatic Impairment:
Severity
![Page 128: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/128.jpg)
4.1. Hepatic Impairment: Severity http://www.ncbi.nlm.nih.gov/pubmed/18293281
■ Child-Pugh scale for □ cirrhosis prognosis, and
□ drug clearance studies
■ Modified version: □ serum bilirubin,
□ serum albumin,
□ ascites,
□ encephalopathy, and
□ prothrombin time.
■ Each measure is scored 1-3,
with 3 indicating the most severe impairment.
■ Grades: □ A (5-6 points)
□ B (7 to 9 points)
□ C (10 to 15 points)
![Page 129: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/129.jpg)
4.2. Hepatic Impairment:
Antidepressants
![Page 130: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/130.jpg)
4.2. Hepatic Impairment: Antidepressants
4.2.1. Lack of Studies
4.2.2. Contraindications
4.2.3. Dose Corrections
4.2.4. Recent Drugs
![Page 131: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/131.jpg)
4.2.1. Hepatic Impairment: Lack of Studies
■ Studies are very limited.
■ Few articles address this issue:
□ One review on DDIs: contraindications http://www.ncbi.nlm.nih.gov/pubmed/25196459
□ One review on pharmacokinetics during hepatic impairment: dose corrections http://www.ncbi.nlm.nih.gov/pubmed/25248846
![Page 132: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/132.jpg)
4.2.2. Hepatic Impairment: Contraindications
■ Absolute contraindications: agomelatine ■ Relative contraindications:
On rare occasions, other antidepressants have been associated with life-threatening hepatotoxicity:□ bupropion, □ duloxetine,□ TCAs, and □ trazadone.Avoid them on patients with:
● history of liver injury, or ● ↑ liver enzymes.http://www.ncbi.nlm.nih.gov/pubmed/25196459
![Page 133: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/133.jpg)
4.2. Hepatic Impairment: Dose Correction■ Lower maximum doses: http://www.ncbi.nlm.nih.gov/pubmed/25248846
□ TCAs: ● amitriptyline: 100 mg/day● desipramine: 150 mg/day● imipramine: 150 mg/day● nortriptyline: 150 mg/day
□ SSRIs: ● citalopram: 20 mg/day● escitalopram: 10 mg/day● fluoxetine: 40 mg/day● fluvoxamine: 150 mg/day● paroxetine: 40 mg/day● sertraline: 100 mg/day
□ SNRIs: ● desvenlafaxine: 100 mg/day● duloxetine: 20 mg/day● venlafaxine: 100 mg/day
□ Others: ● bupropion: 150 mg/day● mirtazapine: 30 mg/day● trazadone 400 mg/day
![Page 134: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/134.jpg)
4.2.4. Hepatic Impairment: Recent Drugs
■ Vilazodone: no need for D correction
http://www.ncbi.nlm.nih.gov/pubmed/25474324
■ Vortioxetine: no need for D correction
in mild-to-moderate hepatic impairmenthttp://www.ncbi.nlm.nih.gov/pubmed/24165478
![Page 135: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/135.jpg)
5. Pregnancy
![Page 136: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/136.jpg)
5. Pregnancy
■ Pregnancy influences some metabolic
enzymes: http://www.ncbi.nlm.nih.gov/pubmed/17696806
□ ↓ activity: CYP1A2 and
CYP2C19
□ ↑ activity: CYP2B6,
CYP2C9,
CYP2D6,
CYP3A4 and
UGT1A4 (probably).
![Page 137: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/137.jpg)
5. Pregnancy
■ Few antidepressant pharmacokinetic studies
have been conducted during pregnancy.
■ After 20 weeks ↑ D for:
□ TCAs: ● clomipramine
● imipramine
● nortriptyline
(Use TDM and ↓ D after delivery.)
□ SSRIs: ● citalopram
● fluoxetine
● fluvoxamine
● paroxetine
● sertraline http://www.ncbi.nlm.nih.gov/pubmed/24525634
![Page 138: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/138.jpg)
6. Do Not Forget
![Page 139: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/139.jpg)
6. Do Not Forget6.1. Some Antidepressants are Inhibitors
6.2. Other Drugs May Influence Antidepressants
![Page 140: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/140.jpg)
6.1. Some Antidepressants are
Inhibitors
![Page 141: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/141.jpg)
6.1. Some Antidepressants are Inhibitors
■ Fluoxetine and fluvoxamine inhibit several CYPs.
Norfluoxetine stays for months after discontinuation
■ Some antidepressants are CYP2D6 inhibitors, so
be very careful when adding them to TCAs:
□ Potent CYP2D6 inhibitors: ● fluoxetine
● paroxetine
□ Moderate CYP2D6 inhibitors: ● bupropion
● duloxetine
□ Mild CYP2D6 inhibitors: ● fluvoxamine
● sertraline (dose-related)
□ Rarely relevant CYP2D6 inhibitors: ● citalopram
● escitalopram
● venlafaxine
■ CYP2C19 inhibitors: ● fluvoxamine: potent
● fluoxetine: weak to moderate
![Page 142: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/142.jpg)
6.2. Other Drugs May Influence
Antidepressants
![Page 143: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/143.jpg)
6.2. Other Drugs May Influence Antidepressants
■ Pregnancy: review slide.
■ AED inducers may eliminate antidepressant efficacy:
□ Do not prescribe bupropion.
□ Not well studied but likely to have major effects on:
● reboxetine
● sertraline
● trazadone
● vilazadone
□ Use antidepressant TDM and/or ↑ D (≥2-3 x) see slides:
● mirtazapine
● TCAs
● vortioxetine
![Page 144: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/144.jpg)
References for Antidepressant Pharmacokinetics
1) 2015 article http://www.ncbi.nlm.nih.gov/pubmed/257458190 with pdf
http://uknowledge.uky.edu/psychiatry_facpub/37/ is the most updated on
induction by AEDs.
2) 2014 article http://www.ncbi.nlm.nih.gov/pubmed/25196459 with pdf
http://uknowledge.uky.edu/psychiatry_facpub/40/ has the best tables for all
antidepressant pharmacokinetics and focuses on AED DDIs.
3) 2014 article http://www.ncbi.nlm.nih.gov/pubmed/24494611 with pdf
http://uknowledge.uky.edu/psychiatry_facpub/42/ focuses on DDI between
second-generation antidepressants and second-generation
antipsychotics.
4) Spina’s 2008 article on SSRI DDIs http://www.ncbi.nlm.nih.gov/pubmed/18691982
5) Spina’s 2012 article on DDI of newer second-generation
antidepressants http://www.ncbi.nlm.nih.gov/pubmed/22171584
![Page 145: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/145.jpg)
Questions
-Please review the 10 questions in the pdf titled “Questions
on the Presentation Pharmacokinetics of Antidepressants”.
-You will find the answers on the last slide after the “Thank
you slide”. No peeking until you have answered all
the questions.
-If you do not answer all the questions correctly, please
review the Power Point presentation once again
to reinforce the pharmacological concepts.
![Page 146: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/146.jpg)
Thank you
![Page 147: Pharmacokinetics of Antidepressants - INHN: Homeinhn.org/fileadmin/Programs/De_Leon_Antidepressant...Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives](https://reader030.vdocuments.us/reader030/viewer/2022040203/5e8474362c617f398761f08a/html5/thumbnails/147.jpg)
Answers
1. A 6. A
2. D 7. D
3. C 8. B
4. A 9. D
5. C 10. A